revis
guidelin
initi
chines
thorac
societi
ct
chines
medic
associ
cma
overal
framework
main
content
updat
guidelin
final
follow
facetofac
work
meet
onlin
video
confer
expert
special
methodolog
provid
train
standard
literatur
search
grade
evid
specialist
contribut
guidelin
level
evid
grade
recommend
base
infecti
diseas
societi
americaamerican
thorac
societi
idsaat
guidelin
cap
level
evid
repres
assess
qualiti
studi
evid
grade
recommend
refer
assess
degre
benefit
intervent
outweigh
risk
gener
speak
higher
evid
level
stronger
grade
recommend
fulli
correspond
willing
valu
patient
well
resourc
consumpt
also
consid
make
recommend
tabl
guidelin
document
compos
section
core
panel
member
respons
separ
group
prepar
first
draft
search
review
relev
domest
intern
literatur
evalu
evid
level
unifi
standard
grade
recommend
decid
vote
member
particip
prepar
guidelin
princip
writer
respons
summar
modif
first
draft
process
facetofac
work
meet
held
discuss
revis
draft
three
round
consult
conduct
solicit
advic
opinion
specialist
specialti
group
within
ct
cma
specialist
relev
disciplin
distribut
antimicrobi
resist
profil
cap
pathogen
significantli
differ
across
differ
countri
region
chang
time
current
result
sever
epidemiolog
survey
cap
conduct
level
high
evid
welldesign
random
control
trial
rct
authorit
guidelin
high
qualiti
systemat
review
metaanalys
level
ii
moder
evid
rct
limit
eg
trial
without
alloc
conceal
nonblind
loss
followup
report
cohort
studi
case
seri
casecontrol
studi
level
iii
low
evid
case
report
expert
opinion
vitro
antimicrobi
suscept
studi
without
clinic
data
grade
recommend
strong
patient
physician
polici
maker
adopt
recommend
action
recommend
adopt
major
individu
decis
made
consider
specif
condit
patient
reflect
hisher
valu
willing
c
weak
insuffici
evid
decis
must
made
via
mutual
discuss
involv
patient
physician
polici
maker
chines
adult
shown
mycoplasma
pneumonia
streptococcu
pneumonia
import
pathogen
cap
adult
china
common
pathogen
includ
haemophilu
influenza
chlamydia
pneumonia
klebsiella
pneumonia
staphylococcu
aureu
pseudomona
aeruginosa
acinetobact
baumannii
infrequ
isol
china
small
number
case
communityacquir
methicillinresist
aureu
camrsa
pneumonia
report
children
teenag
camrsa
identifi
antimicrobi
resist
surveil
communityacquir
respiratori
tract
pathogen
adult
conduct
special
popul
elderli
patient
patient
underli
diseas
eg
congest
heart
failur
cardiovascular
cerebrovascular
diseas
chronic
respiratori
system
diseas
kidney
failur
diabet
mellitu
gramneg
bacteria
k
pneumonia
escherichia
coli
common
develop
applic
viru
detect
technolog
role
respiratori
tract
virus
gradual
gain
attent
aetiolog
cap
chines
adult
result
sever
recent
publish
multicent
studi
show
detect
rate
virus
chines
adult
cap
patient
influenza
viru
account
largest
proport
contribut
virus
includ
parainfluenza
viru
rhinoviru
adenoviru
human
metapneumoviru
hmpv
respiratori
syncyti
viru
rsv
among
patient
posit
test
result
virus
could
concomit
infect
caus
bacteria
atyp
pathogen
consid
resist
profil
major
pathogen
high
percentag
pneumonia
resist
macrolid
found
chines
adult
cap
patient
import
characterist
differ
european
american
countri
two
nationwid
multicent
survey
adult
cap
conduct
show
pneumonia
isol
resist
macrolid
recent
result
multicent
communityacquir
respiratori
tract
infect
pathogen
surveil
cartip
studi
adult
conduct
urban
tertiari
hospit
china
show
pneumonia
isol
resist
azithromycin
minimum
inhibitori
concentr
requir
inhibit
growth
organ
mic
mgl
isol
resist
clarithromycin
european
american
countri
pneumonia
isol
resist
erythromycin
azithromycin
respect
moreov
pneumonia
isol
resist
oral
penicillin
resist
secondgener
cephalosporin
china
howev
rel
low
percentag
pneumonia
isol
resist
inject
penicillin
thirdgener
cephalosporin
respect
high
percentag
mycoplasma
pneumonia
strain
resist
macrolid
anoth
import
characterist
aetiolog
cap
china
differ
countri
studi
result
show
mycoplasma
strain
isol
chines
adult
cap
patient
resist
erythromycin
resist
azithromycin
infect
caus
antibioticresist
mycoplasma
may
prolong
durat
fever
antiinfect
treatment
addit
china
mycoplasma
strain
isol
japanes
adult
teenag
cap
patient
resist
macrolid
macrolidesresist
pneumonia
also
report
franc
canada
unit
state
spain
germani
pneumonia
highli
resist
macrolid
china
remain
suscept
doxycyclin
minocyclin
quinolon
onset
commun
b
relev
clinic
manifest
pneumonia
new
onset
cough
expector
aggrav
exist
symptom
respiratori
tract
diseas
without
purul
sputum
chest
pain
dyspnea
hemoptysi
fever
sign
pulmonari
consolid
andor
moist
rale
peripher
white
blood
cell
count
wbc
l
l
without
left
shift
c
chest
radiograph
show
new
patchi
infiltr
lobar
segment
consolid
groundglass
opac
interstiti
chang
without
pleural
effus
clinic
diagnosi
establish
patient
satisfi
criterion
criterion
c
one
condit
criterion
b
meanwhil
tuberculosi
pulmonari
tumour
noninfecti
interstiti
lung
diseas
pulmonari
edema
atelectasi
pulmonari
embol
pulmonari
eosinophilia
pulmonari
vascul
exclud
step
determin
whether
diagnosi
cap
valid
patient
clinic
suspect
cap
possibl
unusu
infect
tuberculosi
noninfecti
caus
must
consid
step
evalu
sever
cap
select
locat
treatment
step
predict
potenti
pathogen
cap
risk
antibiot
resist
tabl
consid
patient
age
season
onset
underli
diseas
risk
factor
symptom
sign
characterist
chest
imag
xray
film
ct
laboratori
test
sever
cap
prior
antibacteri
therapi
step
arrang
reason
etiolog
test
initi
empir
antiinfect
treatment
time
manner
step
evalu
effect
empir
antiinfect
treatment
cap
dynam
manner
investig
caus
initi
treatment
fail
adjust
treatment
protocol
promptli
step
follow
treatment
provid
educ
health
mainten
cap
ev
eri
ty
c
ri
ter
ia
f
ho
p
ta
l
adm
io
n
di
agno
ti
c
cr
eri
f
evalu
cap
sever
crucial
select
appropri
locat
treatment
initi
empir
antimicrobi
agent
well
adjunct
support
treatment
score
system
cap
sever
differ
tabl
use
aid
evalu
provid
support
clinic
diagnosi
treatment
physician
take
clinic
experi
consider
make
judgment
monitor
diseas
progress
dynam
manner
ii
c
disturb
conscious
u
urea
nitrogen
r
respiratori
rate
b
blood
pressur
age
pneumonia
sever
index
psi
score
system
underestim
risk
death
sever
influenza
pneumonia
oxygen
index
combin
absolut
reduct
peripher
blood
lymphocyt
superior
psi
predict
risk
death
due
influenza
pneumonia
ii
b
score
recommend
standard
decid
whether
patient
hospit
score
point
theoret
patient
receiv
outpati
treatment
score
point
patient
recommend
receiv
inpati
treatment
extramur
treatment
close
followup
score
point
patient
hospit
howev
factor
patient
age
underli
diseas
socioeconom
statu
gastrointestin
function
treatment
complianc
also
taken
account
comprehens
evalu
ii
b
criteria
diagnosi
sever
cap
patient
meet
major
criteria
minor
criteria
could
diagnos
sever
pneumonia
need
close
monitor
activ
treatment
also
recommend
patient
hospit
icu
applic
ii
acut
onset
high
fever
potenti
shiver
purul
sputum
brown
bloodi
sputum
chest
pain
signific
increas
peripher
wbc
increas
creactiv
protein
crp
sign
pulmonari
consolid
moist
rale
radiograph
show
alveolar
infiltr
lobar
segment
distribut
consolid
mycoplasma
chlamydia
year
age
underli
diseas
continu
cough
sputum
bacteria
discov
sputum
smear
test
pulmonari
sign
peripher
wbc
l
radiograph
may
show
lesion
upper
lung
field
lung
centrilobular
nodul
treeinbud
sign
groundglass
opac
thicken
bronchial
wall
may
show
sign
consolid
diseas
progress
viru
mostli
season
may
histori
exposur
epidem
cluster
outbreak
acut
upper
respiratori
tract
symptom
myalgia
normal
decreas
peripher
wbc
procalcitonin
pct
ngml
unrespons
treatment
antibacteri
agent
radiograph
show
bilater
interstiti
exud
multipl
lobe
andor
groundglass
opac
may
accompani
consolid
iv
patient
without
improv
activ
antiinfect
therapi
requir
differenti
diagnosi
noninfecti
pulmonari
lesion
tumour
vascul
interstiti
lung
diseas
iii
b
see
tabl
primari
test
method
cap
pathogen
correspond
diagnost
criteria
ecti
anti
nf
ect
ther
ap
es
f
c
ap
clinic
diagnosi
cap
establish
etiolog
test
sampl
arrang
appropri
potenti
pathogen
assess
term
patient
age
underli
diseas
clinic
characterist
result
laboratori
radiographi
test
sever
diseas
hepat
renal
function
histori
medic
antimicrobi
suscept
profil
evalu
risk
antibiot
resist
select
appropri
antiinfect
agent
dose
regimen
tabl
initi
empir
antibacteri
therapi
administ
promptli
import
note
epidemiolog
distribut
antimicrobi
resist
profil
pathogen
may
differ
differ
region
china
antiinfect
drug
list
tabl
option
initi
empir
therapi
treatment
recommend
theoret
select
therapi
specif
patient
must
base
actual
situat
local
healthcar
facil
addit
pharmacokinet
pharmacodynam
properti
antibacteri
agent
must
taken
consider
timedepend
antibacteri
agent
penicillin
cephalosporin
monobactam
carbapenem
bactericid
abil
almost
satur
time
mic
mic
time
mic
import
determin
efficaci
better
clinic
efficaci
achiev
multipl
dose
per
day
base
halfliv
meanwhil
bactericid
abil
concentrationdepend
antibacteri
agent
aminoglycosid
quinolon
increas
drug
concentr
effect
improv
higher
peak
drug
concentr
therefor
drug
usual
administ
daili
order
increas
drug
activ
decreas
risk
drug
resist
kidney
injuri
caus
aminoglycosid
recommend
guidelin
empir
antiinfect
treatment
cap
provid
follow
first
dose
antiinfect
agent
use
earli
possibl
diagnosi
cap
establish
fluoresc
smear
microscopi
sensit
ziehlneelsen
stain
sensit
mycobacteria
cultur
superior
smear
microscopi
vitro
suscept
test
perform
timeconsum
complex
higher
biolog
safeti
requir
laboratori
order
improv
efficaci
decreas
mortal
hospit
stay
howev
import
note
correct
diagnosi
prerequisit
physician
ignor
necessari
differenti
diagnosi
purpos
earli
diagnosi
antiinfect
therapi
usual
termin
day
fever
reliev
primari
respiratori
tract
symptom
improv
significantli
howev
durat
therapi
differ
base
sever
diseas
treatment
respons
complic
pathogen
necessari
use
chest
xray
ct
indic
termin
antibacteri
agent
gener
durat
therapi
day
patient
mild
moder
cap
could
reason
prolong
patient
sever
cap
extrapulmonari
complic
durat
therapi
prolong
day
patient
atyp
pathogen
andor
slow
respons
treatment
aureu
p
aeruginosa
klebsiella
anaerob
bacteria
may
caus
necrosi
lung
tissu
therefor
durat
therapi
may
prolong
day
b
aetiolog
cap
determin
target
therapi
deliv
accord
result
vitro
suscept
test
see
tabl
common
pathogen
cap
common
antiinfect
agent
well
dosag
administr
cap
primari
caus
death
among
infecti
diseas
addit
antiinfect
treatment
target
pathogen
also
necessari
patient
moder
sever
cap
receiv
adjunct
therapi
rehydr
mainten
fluid
electrolyt
balanc
nutrit
support
physic
therapi
ii
b
patient
concomit
low
blood
pressur
earli
fluid
resuscit
import
measur
decreas
mortal
seriou
cap
ii
b
patient
hypoxemia
oxygen
repeat
dose
antibacteri
drug
glucocorticoid
due
chronic
airway
diseas
combin
therapi
recommend
patient
sever
cap
proven
antimicrobi
resist
gener
cephalosporin
cefazolin
cefradin
cephalexin
cefathiamidin
ii
gener
cephalosporin
cefuroxim
cefamandol
cefotiam
cefaclor
cefprozil
iii
gener
cephalosporin
intraven
ceftriaxon
cefotaxim
ceftizoxim
oral
cefdinir
cefixim
cefpodoxim
proxetil
cefditoren
pivoxil
respiratori
quinolon
levofloxacin
moxifloxacin
gemifloxacin
aminopenicillin
amoxicillin
ampicillin
penicillinsblactamaseinhibitor
combin
includ
penicillin
antipseudomon
activ
piperacillin
ticarcillin
amoxicillinclavulan
acid
amoxicillinsulbactam
ampicillinsulbactam
macrolid
azithromycin
clarithromycin
erythromycin
quinolon
antipseudomon
activ
ciprofloxacin
levofloxacin
betalactam
antipseudomon
activ
ceftazidim
cefepim
aztreonam
piperacillin
piperacillintazobactam
ticarcillin
ticarcillinclavulan
acid
cefoperazon
cefoperazonesulbactam
imipenemcilastatin
meropenem
panipenembetamipron
biapenem
week
follow
tmpsmx
month
durat
therapi
month
primari
pulmonari
nocardiosi
ampicillin
g
iv
week
follow
penicillin
v
potassium
gkg
per
day
oral
piperacillin
amoxicillinclavulan
acid
ampicillinsulbactam
piperacillintazobactam
doxycyclin
minocyclin
ceftriaxon
clindamycin
chloramphenicol
azithromycin
erythromycin
moxifloxacin
imipenem
ertapenem
penicillin
g
altern
ampicillin
million
ud
iv
divid
separ
dose
week
gentamicin
mgkg
iv
daili
doxycyclin
minocyclin
tmpsmx
use
prevent
yersinia
pesti
pneumonia
chloramphenicol
effect
high
toxic
cephalosporin
quinolon
effect
anim
model
ciprofloxacin
mg
iv
levofloxacin
mg
iv
daili
doxycyclin
mg
iv
clindamycin
mg
iv
rifampin
mg
iv
switch
oral
therapi
reduc
dosag
improv
ciprofloxacin
mg
oral
twice
daili
clindamycin
mg
oral
rifampin
mg
oral
twice
daili
durat
therapi
penicillin
g
clindamycin
inhibit
product
toxin
rifampin
enter
cerebrospin
fluid
cell
isol
pathogen
suscept
penicillin
penicillin
million
u
iv
given
structur
induct
blactamas
produc
penicillin
ampicillin
use
alon
cephalosporin
tmpsmx
use
erythromycin
azithromycin
borderlin
activ
clarithromycin
effect
moxifloxacin
effect
without
clinic
data
cidofovir
mgkg
iv
daili
week
oral
probenecid
g
given
everi
time
inject
g
oral
probenecid
drug
contraind
serum
creatinin
mgdl
crcl
mlmin
urin
protein
mgl
specif
drug
far
ribavirin
gd
iv
recommend
regular
use
therapi
mainli
symptomat
treatment
includ
fluid
replac
oxygen
therapi
specif
drug
far
therapi
assist
ventil
also
import
improv
outcom
patient
addit
nebul
postur
drainag
chest
physic
therapi
also
use
cap
treatment
ii
b
adjunct
drug
sever
cap
also
includ
glucocorticoid
intraven
immun
globulin
statin
although
current
conclus
evid
effect
ii
b
oxygen
therapi
assist
respir
blood
oxygen
level
hospit
cap
patient
evalu
time
manner
oxygen
therapi
via
nasal
cathet
face
mask
recommend
patient
hypoxemia
order
maintain
blood
oxygen
satur
addit
patient
risk
hypercapnia
oxygen
satur
maintain
obtain
result
blood
ga
analysi
iii
result
recent
studi
show
heat
humidifi
highflow
oxygen
therapi
via
nasal
cathet
lmin
could
also
use
clinic
practic
ii
b
compar
highconcentr
oxygen
therapi
noninvas
ventil
niv
includ
bilevel
posit
airway
pressur
continu
posit
pressur
ventil
decreas
endotrach
intub
rate
mortal
cap
patient
acut
respiratori
failur
improv
oxygen
index
faster
significantli
decreas
incid
multipl
organ
failur
septic
shock
benefit
signific
patient
concomit
chronic
obstruct
pulmonari
diseas
ii
b
howev
cap
patient
acut
respiratori
distress
syndrom
ard
niv
shown
high
failur
rate
improv
prognosi
niv
also
appropri
cap
patient
sever
hypoxemia
oxygen
index
mm
hg
ii
addit
failur
niv
must
recogn
time
niv
failur
indic
niv
improv
respiratori
rate
oxygen
state
within
initi
h
therapi
decreas
blood
carbon
dioxid
level
patient
initi
hypercapnia
oxygen
therapi
switch
tracheal
intub
ventilatorassist
ventil
immedi
ii
mechan
ventil
low
tidal
volum
mlkg
ideal
bodi
weight
use
cap
patient
ard
tracheal
intub
patient
sever
cap
concomit
ard
extracorpor
membran
oxygen
ecmo
use
regular
mechan
ventil
lead
improv
ii
b
indic
ecmo
includ
revers
respiratori
failur
associ
sever
select
antimicrobi
agent
ultim
depend
suscept
test
result
opinion
local
microbiolog
specialist
appropri
dosag
antimicrobi
agent
base
local
data
crcl
creatinin
clearanc
mic
minimum
inhibitori
concentr
mrsa
methicillinresist
aureu
tmpsmx
trimethoprimsulfamethoxazol
cefoxitin
g
iv
cefmetazol
g
cefotetan
g
iv
maximum
dose
g
daili
cefminox
g
iv
b
levofloxacin
moxifloxacin
gemifloxacin
firstlin
therapi
penicillinsuscept
strain
ciprofloxacin
mainli
use
treatment
gramneg
bacteria
includ
h
influenza
c
ticarcillin
g
iv
piperacillin
g
iv
piperacillintazobactam
g
iv
aztreonam
g
iv
ceftazidim
g
iv
cefepim
g
iv
cefoperazon
g
iv
cefoperazonesulbactam
g
imipenemcilastatin
p
aeruginosa
mg
base
imipenem
iv
meropenem
g
iv
panipenembetamipron
g
iv
biapenem
piperacillintazobactam
g
iv
ticarcillinclavulan
acid
g
iv
ampicillinsulbactam
g
iv
amoxicillinclavulan
acid
g
iv
f
imipenemcilastatin
mg
base
imipenem
iv
meropenem
g
iv
ertapenem
g
iv
panipenembetamipron
g
iv
biapenem
g
iv
glucocorticoid
decreas
mortal
cap
patient
complic
septic
shock
hydrocortison
succin
mgday
suggest
base
treatment
septic
shock
drug
stop
promptli
septic
shock
correct
durat
therapi
normal
day
ii
c
initi
therapi
assess
effect
failur
base
patient
respons
treatment
subsequ
manag
provid
accordingli
assess
initi
therapi
includ
follow
aspect
clinic
manifest
includ
respiratori
system
symptom
sign
iii
vital
sign
gener
condit
conscious
bodi
temperatur
respiratori
rate
heart
rate
blood
pressur
gener
laboratori
test
includ
routin
blood
test
blood
biochemistri
blood
ga
analysi
creactiv
protein
procalcitonin
recommend
repeat
creactiv
protein
procalcitonin
routin
blood
test
h
hospit
patient
order
differenti
treatment
failur
slow
respons
therapi
patient
sever
condit
monitor
close
ii
b
microbiolog
test
appropri
repeat
regular
microbiolog
test
molecular
biolog
serolog
assay
use
necessari
effort
made
obtain
etiolog
evid
ii
b
chest
radiographi
recommend
repeat
chest
radiographi
regularli
patient
signific
improv
clinic
symptom
symptom
sign
persist
exacerb
chest
xray
chest
ct
repeat
identifi
chang
lung
lesion
effect
initi
therapi
defin
situat
clinic
condit
patient
stabil
therapi
criteria
must
met
clinic
stabil
subsequ
manag
recommend
effect
initi
therapi
patient
signific
improv
symptom
initi
therapi
appropri
continu
antiinfect
treatment
patient
achiev
clinic
stabil
abl
receiv
oral
therapi
sequenti
therapi
administ
pathogensuscept
oral
prepar
type
antimicrobi
agent
anoth
agent
similar
antibacteri
spectrum
fail
initi
therapi
defin
either
follow
situat
patient
symptom
improv
initi
therapi
requir
altern
antibiot
exacerb
diseas
progress
initi
improv
initi
therapi
ii
epidem
season
februari
may
viru
commonli
seen
adult
without
underli
diseas
incub
period
rel
common
serotyp
similar
pneumonia
caus
influenza
viru
common
immunocompet
adult
patient
sever
condit
primarili
show
pulmonari
consolid
may
associ
groundglass
opac
patchi
nodul
infiltr
unilater
bilater
lung
multipl
lobe
use
tumour
necrosi
factora
antagonist
relev
epidemiolog
histori
includ
contact
contamin
air
condition
air
condition
cool
tower
contamin
potabl
water
hot
recreat
spa
garden
activ
plumb
repair
histori
travel
area
legionella
outbreak
possibl
legionella
pneumonia
suspect
adult
cap
patient
develop
follow
condit
fever
rel
bradycardia
acut
onset
headach
nondruginduc
disturb
conscious
sleepi
nondruginduc
diarrhoea
acut
renal
andor
hepat
impair
hyponatremia
hypophosphatemia
unrespons
blactam
rel
specif
manifest
legionella
pneumonia
chest
radiograph
sharpli
demarc
consolid
intermingl
groundglass
opac
anoth
characterist
legionella
pneumonia
radiograph
progress
within
short
period
time
week
even
though
improv
clinic
symptom
may
take
sever
week
even
month
pulmonari
infiltr
complet
absorb
macrolid
respiratori
quinolon
doxycyclin
monotherapi
appropri
immunocompet
patient
mild
moder
legionella
pneumonia
quinolon
combin
rifampin
macrolid
recommend
patient
sever
condit
monotherapi
fail
immunocompromis
patient
quinolon
combin
macrolid
physician
pay
close
attent
potenti
risk
abnorm
cardiac
electrophysiolog
current
camrsa
pneumonia
rel
rare
mainland
china
small
number
case
report
children
teenag
similarli
among
skin
soft
tissu
infect
caus
aureu
mrsa
account
small
proport
among
pathogen
hospit
cap
patient
proport
mrsa
taiwan
japan
unit
state
accord
survey
estim
incid
camrsa
pneumonia
mainli
pulmonari
involv
subpleur
basal
segment
lung
broad
appear
groundglass
opac
may
associ
consolid
pleural
effus
interlobular
septal
thicken
may
also
appear
ribavirin
combin
interferon
ii
c
peopl
camrsa
pneumonia
sever
diseas
associ
mortal
vulner
popul
includ
patient
individu
close
contact
mrsa
carrier
patient
individu
affect
influenza
viru
prison
profession
athlet
individu
serv
armi
recent
men
sex
men
intraven
drug
user
regular
sauna
user
use
antibacteri
agent
infect
camrsa
pneumonia
progress
rapidli
clinic
symptom
includ
influenzalik
symptom
fever
cough
chest
pain
gastrointestin
symptom
skin
rash
patient
seriou
condit
sever
pneumonia
symptom
hemoptysi
confus
ard
multipl
organ
failur
shock
may
appear
well
complic
acidosi
dissemin
intravascular
coagul
deep
vein
thrombosi
pneumothorax
empyema
pneumatocel
pulmonari
abscess
acut
necrot
pneumonia
radiograph
characterist
camrsa
pneumonia
includ
extens
pulmonari
consolid
multipl
caviti
bilater
lung
camrsa
pneumonia
suspect
influenza
previous
healthi
young
patient
case
cavit
necrot
pneumonia
associ
rapid
increas
pleural
effus
massiv
hemoptysi
neutropenia
andor
erythemat
rash
glycopeptid
linezolid
primari
choic
camrsa
pneumonia
iii
b
current
consensu
definit
cap
elderli
elderli
cap
pneumonia
occur
popul
age
year
incid
elderli
cap
increas
age
clinic
manifest
elderli
cap
atyp
manifest
may
includ
poor
appetit
urinari
incontin
tired
alter
mental
state
typic
manifest
pneumonia
fever
cough
increas
wbcneutrophil
count
may
evid
therefor
miss
diagnosi
misdiagnosi
may
occur
tachypnea
sensit
index
diagnosi
elderli
cap
fever
abovement
atyp
symptom
appear
chest
radiographi
done
earli
possibl
confirm
diagnosi
pneumonia
still
main
pathogen
elderli
cap
possibl
enterobacteriacea
infect
consid
elderli
patient
underli
diseas
congest
heart
failur
cardiovascular
cerebrovascular
diseas
chronic
respiratori
system
diseas
renal
failur
diabet
mellitu
etc
patient
evalu
risk
factor
esblsproduc
enterobacteriacea
empir
treatment
cephamycin
piperacillintazobactam
cefoperazonesulbactam
ertapenem
carbapenem
recommend
patient
high
risk
infect
esblsproduc
enterobacteriacea
iii
b
relev
risk
factor
includ
histori
esblsproduc
bacteri
colon
infect
prior
use
third
gener
cephalosporin
histori
repeat
longterm
hospit
indwel
medic
devic
renal
replac
therapi
elderli
patient
associ
reduc
organ
function
must
monitor
treatment
avoid
side
effect
reduc
renal
excret
may
caus
prolong
halfliv
drug
dosag
reason
adjust
term
crcl
treat
patient
ii
b
contraind
exist
hospit
elderli
cap
patient
evalu
risk
deep
vein
thrombosi
prophylaxi
low
molecular
weight
heparin
administ
necessari
ii
b
treatment
failur
rate
elderli
cap
common
reason
concomit
sever
sepsi
myocardi
infarct
progress
pneumonia
cardiovascular
event
common
elderli
cap
one
reason
increas
mortal
aspir
pneumonia
pulmonari
infecti
lesion
caus
aspir
food
oropharyng
secret
gastric
content
throat
lower
respiratori
tract
includ
chemic
inflamm
lung
due
aspir
steril
gastric
fluid
major
case
aspir
pneumonia
caus
silent
aspir
account
around
elderli
cap
follow
point
note
make
diagnosi
aspir
pneumonia
whether
risk
factor
aspir
eg
disturb
conscious
due
cerebrovascular
diseas
reason
dysphagia
periodont
diseas
poor
oral
hygien
whether
chest
radiograph
show
primari
lesion
posterior
segment
upper
lobe
dorsal
basal
segment
lower
lobe
hypostat
pneumonia
aspir
pneumonia
mostli
caus
infect
anaerob
bacteria
gramneg
bacteria
aureu
treatment
cover
pathogen
base
sever
diseas
use
antimicrobi
agent
antianaerob
activ
amoxicillinclavulan
acid
ampicillinsulbactam
moxifloxacin
carbapenem
combin
metronidazol
clindamycin
ii
target
treatment
administ
result
sputum
cultur
antimicrobi
suscept
test
avail
intens
care
requir
elderli
patient
risk
factor
aspir
order
reduc
incid
aspir
pneumonia
specif
head
bed
elev
longterm
bedridden
patient
contraind
patient
appropri
posit
feed
patient
oral
hygien
maintain
reduc
bacteri
colon
oropharyng
area
elderli
patient
sever
dysphagia
alreadi
experienc
aspir
physician
evalu
risk
benefit
nasal
feed
via
indwel
gastric
tube
antipsychot
drug
antihistamin
anticholinerg
agent
avoid
decreas
ii
b
smoke
cessat
avoid
excess
alcohol
drink
adequ
nutrit
good
oral
health
help
prevent
pneumonia
iii
b
good
hand
hygien
habit
maintain
episod
respiratori
tract
symptom
cough
sneez
wear
mask
use
tissu
elbow
cloth
cover
nose
mouth
reduc
dissemin
respiratori
tract
pathogen
iii
vaccin
pneumonia
reduc
risk
pneumonia
specif
popul
pneumonia
vaccin
current
use
includ
pneumococc
polysaccharid
vaccin
ppv
pneumococc
conjug
vaccin
pcv
china
pneumococc
polysaccharid
vaccin
market
effect
prevent
invas
pneumonia
infect
recommend
follow
popul
b
age
year
age
year
chronic
pulmonari
diseas
chronic
cardiovascular
diseas
diabet
mellitu
chronic
renal
failur
nephrot
syndrom
chronic
hepat
diseas
includ
hepat
cirrhosi
alcohol
cochlear
implant
cerebrospin
fluid
leakag
immunodefici
function
organ
asplenia
longterm
resid
nurs
home
medic
institut
smoker
patient
one
dose
vaccin
intramuscular
subcutan
inject
recommend
usual
repeat
vaccin
advis
immunocompet
individu
although
appropri
individu
year
age
chronic
renal
failur
nephrot
syndrom
function
organ
asplenia
immunodefici
least
interv
two
dose
repeat
vaccin
necessari
individu
least
year
age
time
first
vaccin
b
pneumococc
conjug
vaccin
cover
pneumonia
serotyp
china
associ
excel
immunogen
avail
china
market
vaccin
strategi
adult
age
year
receiv
pneumonia
vaccin
receiv
dose
dose
within
month
afterward
adult
age
year
receiv
one
dose
receiv
dose
least
one
year
latest
dose
adult
receiv
age
receiv
year
old
least
one
year
last
vaccin
repeat
vaccin
least
month
later
least
interv
two
dose
b
influenza
vaccin
prevent
influenza
reduc
influenzaassoci
symptom
also
protect
effect
influenza
pneumonia
bacteri
pneumonia
secondari
influenza
target
popul
influenza
vaccin
broader
pneumonia
vaccin
see
chines
guidelin
diagnosi
treatment
influenza
visit
websit
nation
influenza
center
detail
one
dose
influenza
vaccin
recommend
per
annual
influenza
season
combin
pneumococc
vaccin
influenza
vaccin
decreas
mortal
elderli
patient
ii
b
